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Abstract  
A 61-year old female patient who was referred to the endocrine clinic for evaluation of an elevated alkaline phosphatase. She was originally referred 
to gastroenterology (GI), however no GI causes of elevated alkaline phosphatase was found. Upon fractionation, it was noted that she had elevation 
in bone specific alkaline phosphatase. Past history was significant for hypertension, atrial fibrillation and menopause 6 years ago. She was also noted 
to have multiple drug allergies manifesting as urticaria and flushing. Review of the past records revealed a persistently elevated alkaline phosphatase 
over the last two years. She had no history of falls or fractures. Computed tomography (CT) abdomen done to rule out biliary pathology, revealed 
osteosclerotic and osteolytic lesion in the pelvis concerning neoplastic disease. Bone marrow biopsy however, was negative for cancer but consistent 
with systemic mastocytosis (SM). Dual Energy X-ray absorbimetery (DEXA) scan revealed osteoporosis Serum tryptase levels were elevated; further 
genetic analysis showed a positive CKIT D816 mutation. She was started on bisphosphonates (initially alendronate and then ibandronate). Upon 
follow up at two years she had not experienced any fractures and her bone mineral density also had improved significantly. 
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Osteoporosis is defined as a disease characterized by low bone mass 
and microarchitectural deterioration of bone tissue leading to 
enhanced bone fragility and a consequent increase in fracture risk [1]. 
Secondary osteoporosis is defined as osteoporosis which occurs 
secondary to a disease state or medication [2]. About 30% of 
postmenopausal women and 50-80% of men have factors contributing 
to osteoporosis. Systemic mastocytosis is a rare cause of secondary 
osteoporosis however it may be underdiagnosed due to a lack of 
awareness [3, 4]. Moreover, treatment of secondary factors of 
osteoporosis may affect the response to antiresorptive medications 
[5]. Physicians should consider SM in patients with unexplained 
osteoporosis and symptoms of mast cell release (flushing, urticarial, 
diarrhoea, and angioedema) [6]. Prompt diagnosis of this disorder 




Patient and observation 
 
A 61-year old Caucasian female who was referred to the endocrine 
clinic for evaluation of elevated serum alkaline phosphatase. She was 
referred to GI, however, no GI cause of elevated alkaline phosphatase 
was found. Fractionation of alkaline phosphatase showed elevation in 
bone specific alkaline phosphatase. She had a past medical history 
significant for hypertension, atrial fibrillation and menopause 6 years 
ago. She was also noted to have allergies to multiple medications, the 
reactions manifesting as urticaria and flushing. She also complained 
of diffuse pain in her back and extremities. Family history was 
significant for maternal osteoporosis. Upon review of her medical 
records, it was noted that her alkaline phosphatase was persistently 
elevated over the last two years. Ultrasound (USG) of abdomen to 
evaluate gall bladder disease showed a heterogeneous appearance of 
the liver, but no gall bladder disease. CT abdomen did not reveal any 
abnormalities of the liver, however it did show diffuse sclerosis of the 
pelvis (Figure 1). As this was concerning for bone neoplasia, a positron 
emission tomography (PET) scan was done which did not reveal any 
abnormal uptake. Laboratory assessment showed an elevated bone 
specific alkaline phosphatase, urinary N telopeptide along with a 
normal parathyroid hormone (PTH) and vitamin D, indicating 
increased resorption of the bone (Table 1). DEXA scan revealed 
marked discrepancy between bone mineral density in the femoral neck 
and lumbar spine versus the distal forearm. T-score at the distal 
forearm was consistent with the diagnosis of osteoporosis (Table 2). 
Bone marrow biopsy revealed multifocal dense mast cell masses with 
predominantly spindle cell morphology most consistent with indolent 
SM. Immunohistochemical staining was positive for tryptase and CD25 
(Figure 2). Genetic testing revealed a positive D816 mutation. She was 
treated with doxepin and ranitidine for her flushing and urticaria. For 
osteoporosis, antiresorptive therapy with alendronate 70 mg weekly 
was initiated, this was later changed to ibandronate 150 mg monthly 
upon patient's request. Follow up bone densitometry 2 years later 
showed marked improvement in bone mineral density (BMD) at the 






Mastocytosis refers to a group of disorders characterized by excessive 
mast cell accumulation in one or more tissues. It is subdivided into 
cutaneous mastocytosis when it is limited only to the skin and SM 
when it infiltrates extra-cutaneous organs [7]. Cutaneous 
mastocytosis was first described in 1869 by Nettleship. It is the most 
common form in childhood and often resolves by itself [8]. SM was 
first described in 1933 by Touraine. It is more common in adults and 
is characterized by involvement of at least 1 extra-cutaneous organ. 
The most commonly involved organs are bone, gastrointestinal tract, 
spleen, and lymph nodes. SM has been further classified into indolent 
SM, SM with an associated hematological non mast cell disorder (SM-
AHNMD), aggressive mastocytosis (ASM) and mast cell leukemia 
(MCL). The most common form of SM is indolent SM [9]. Clinical 
features are variable and depend on the system involved, effects of 
the mediators and the mast cell burden. Cutaneous involvement is 
very common and seen in over 90% cases. It manifests most 
commonly as urticaria, flushing, and angioedema. Our patient had 
urticaria and flushing for many years, we suspect that these were 
wrongly attributed as allergic reactions to medications. Involvement 
of the gastrointestinal tract leads to nausea, vomiting, diarrhea, and 
abdominal pain. Rarely hepatopathy, portal hypertension ascites, 
hypersplenism, and malabsorption may also be seen [10, 11]. 
  
Skeletal involvement occurs in 70% of patients with SM [10]. Van der 
Veer et al. studied 157 patients with indolent SM and found a high 
prevalence of osteoporotic fractures (38%). Male preponderance was 
noted, with 62% of the men having osteoporotic manifestations (BMD 
of < -2.5 or osteoporotic fracture). Older age, men and elevated 
urinary methyl histamine levels were independently linked to 
osteoporotic fractures [12]. Bone pain secondary to bone marrow 
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involvement is the hallmark of SM. SM should be strongly considered 
in any patient presenting with debilitating bone pain and unexplained 
osteoporosis. The most common site of involvement is the lumbar 
spine, indicating the preferential involvement of trabecular bone. This 
could be due to the tendency of the mast cells to colonize the bone 
marrow [13]. Radiologically, bone involvement is most commonly 
characterized by focal osteosclerosis and osteolytic bone lesions 
affecting the axial skeleton as well as the long bones. This may be 
confused with Pagets disease, lymphoma or diffuse metastatic disease 
as seen in our patient. Rarely multiple or solitary osteolytic lesions are 
also seen [14]. Osteoporosis in SM could be either due to neoplastic 
infiltration of mast cells or due to the effect of inflammatory mediators 
secreted by the mast cells. Histamine, tryptase and heparin can 
directly activate the osteoclasts as well as activating the RANK-L 
pathway which in turn promotes bone resorption. Interleukin (IL)-1, 
IL-6, tumor necrosis factor (TNF)-alpha can activate osteoclasts 
through the RANK-L pathway, and also inhibit osteoblasts thereby 
increasing bone resorption and decreasing bone formation. Increased 
levels of sclerostin and DKK-1 which are inhibitors of the Wnt pathway 
have been noted in some studies which may decrease bone formation 
[13]. SM should be suspected in any patient with unexplained 
osteoporosis with symptoms of mast cell mediator release. 
  
Elevated levels of tryptase re observed in 95% of indolent SM cases, 
however chronic kidney disease, urticaria, psoriasis, hematological 
disorders, onchocercosis and ischemic myocardial disease can also 
increase tryptase levels. Urinary histamine metabolites can be helpful 
in diagnosis of SM where the tryptase is normal, however these 
metabolites can be increased in patients with gastric carcinoid and 
Zollinger Ellison syndrome [13, 15]. The diagnosis can be definitively 
established by a bone marrow biopsy. Typically multifocal dense cell 
masses of mast cells are seen, sometimes spindle shaped or atypical 
mast cells may also be seen [16]. Genetic analysis for D816VKIT is 
positive in about 78% of indolent SM cases [17]. Diagnosis is based 
on meeting at least 1 major and 1 minor or three minor WHO criteria 
as outlined in Table 3. Treatment of SM is multipronged, aimed at, 
alleviating the symptoms using antihistamines and mast cell 
stabilizers, using cytoreductive agents to control the mast cell 
proliferation and anti-resorptive agents to treat the osteoporosis [13]. 
Since increase in bone resorption through activation of osteoclasts and 
RANK-L pathway is the main mechanism of causation of osteoporosis 
in SM, antiresorptive agents are the treatment of choice. Among 
bisphosphonates zoledronic acid has been shown to increase bone 
mineral density the most. The improvement is most significant in the 
lumbar spine as seen in our patient who had a 14% increase in BMD 
in the lumbar spine over 2 years [18]. Laroche et al. studied 8 patients 
treated with pamidronate and interferon alpha and found that spinal 
bone mineral density (BMD) increased by 15% in 2 years whereas the 
2 patients treated with pamidronate alone had only a 2% increase in 
BMD. There was no difference in the decline of bone remodeling 
markers in both groups [19]. Orsolini et al. studied the use of 
denosumab, a RANK-L inhibitor in 4 patients and noted an 






SM is a rare cause of secondary osteoporosis. It needs to be 
considered in the differential diagnosis of patients with unexplained 
osteoporosis and symptoms of mast cell release, unexplained 
vertebral fractures or osteoporosis with severe bone pain. Elevated 
tryptase levels although, consistent with SM can also be seen in 
chronic urticaria, hematological disorders, chronic kidney disease and 
ischemic myocardial disease. Urinary histamine metabolites may be 
elevated and are useful in rare cases of SM where tryptase levels are 
normal. Diagnosis can be definitively established by bone marrow 
biopsy. Bisphosphonates are the mainstay of treatment of 
osteoporosis secondary to SM and improve the BMD significantly. 
RANK-L inhibitors (denosumab) can be an alternative in patients who 
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Table 1: laboratory assessment at presentation 
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Table 2: comparison of bone mineral density at diagnosis and two 
years later  
Table 3: World Health Organization (WHO) diagnostic criteria for 
Systemic Mastocytosis(SM)  
Figure 1: computed Tomography (CT) of the abdomen and pelvis 
showing osteosclerosis of pelvic bones 
Figure 2: A) paratrabecular mast cell inifltrates occupying the bone 
marrow; B) neoplastic spindle cell infiltrate in the bone marrow; 
C) positive staining to tryptase confirming mast cell lineage; 
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Table 1: laboratory assessment at presentation 
S.No. Test Result Normal value 
1. Bone alkaline phosphatase 36.1 0-21.3 mcg/lt 
2. Alkaline phosphatase  isoforms 155 25-165 IU/lt 
  Liver fraction 28 26-86% 
  Bone fraction 72 11-68% 
  Intestinal fraction 0 0-16% 
3. 25 (OH) Vitamin D 48.9 32-100 ng/ml 
4. Parathyroid, intact 50.5 8-97 pg/ml 
5. Urinary N-telopeptide 2692 19-63 nmol BCE 
6. N-telopeptide/creatnine ratio 65 5-65 nM BCE/mM Cr 
7. Serum tryptase 158 (1-11.5 mcg/lt) 
mcg=micro grams; lt=litre; IU=international units; ng=nanograms; ml=milliliter; 























Table 2: comparison of bone mineral density at diagnosis and two years later 
  At presentation 2 years later 
  Bone mineral density 
(grams/square cm) T score Bone mineral density T score 
Lumbar spine 0.922 -2 1.154 -0.2 
Left femoral neck 1.099 0.4 1.259 1.6 










Table 3: WHO diagnostic criteria for SM 
Major Criteria Multifocal dense aggregates of 15 or more mast cells as detected with tryptase or other special stains in bone 
marrow or other extra cutaneous organs. 
Minor criteria Atypical morphology or spindle shapes in >25 percent of the mast cells in bone marrow sections, bone 
marrow aspirate, or other extra cutaneous tissues 
Mutational analysis of KIT showing a codon 816 mutation (eg, Asp816Val) in bone marrow, blood, or extra 
cutaneous organs 
Bone marrow or extra cutaneous mast cells expressing the surface markers CD2, CD25 or both. Baseline 
serum tryptase levels >20ng/ml. This does not apply to AHNMD 
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Figure 1: computed Tomography (CT) of the abdomen and pelvis showing osteosclerosis of pelvic bones 
 
 
Figure 2: A) paratrabecular mast cell inifltrates occupying the bone marrow; B) neoplastic spindle cell infiltrate in the 
bone marrow; C) positive staining to tryptase confirming mast cell lineage; D) positive staining to CD 25 consistent 
with neoplastic mast cells 
 
